Head to Head Survey: Microbot Medical (NASDAQ:MBOT) versus Hypertension Diagnostics (OTCMKTS:HDII)

Hypertension Diagnostics (OTCMKTS:HDII) and Microbot Medical (NASDAQ:MBOT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk.

Volatility and Risk

Hypertension Diagnostics has a beta of 1.24, suggesting that its stock price is 24% more volatile than the S&P 500. Comparatively, Microbot Medical has a beta of 1.4, suggesting that its stock price is 40% more volatile than the S&P 500.

Profitability

This table compares Hypertension Diagnostics and Microbot Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hypertension Diagnostics	N/A	N/A	N/A
Microbot Medical	N/A	-218.30%	-158.17%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Hypertension Diagnostics and Microbot Medical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hypertension Diagnostics	0	0	0	0	0.00
Microbot Medical	0	0	1	0	3.00

Microbot Medical has a consensus price target of $9.00, suggesting a potential upside of 276.57%. Given Microbot Medical’s stronger consensus rating and higher probable upside, analysts plainly believe Microbot Medical is more favorable than Hypertension Diagnostics.

Insider and Institutional Ownership

16.3% of Microbot Medical shares are held by institutional investors. 40.0% of Hypertension Diagnostics shares are held by insiders. Comparatively, 5.4% of Microbot Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Hypertension Diagnostics and Microbot Medical”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hypertension Diagnostics	N/A	N/A	N/A	N/A	N/A
Microbot Medical	N/A	N/A	-$10.74 million	($0.74)	-3.23

Summary

Microbot Medical beats Hypertension Diagnostics on 5 of the 8 factors compared between the two stocks.

About Hypertension Diagnostics

Hypertension Diagnostics, Inc. designs, develops, manufactures, and markets proprietary noninvasive medical devices that detect subtle changes in the elasticity of arteries in the United States and internationally. It offers CVProfilor, which allows a physician to non-invasively assess the elasticity of small and large arteries, of which small artery elasticity is the earliest and sensitive marker of cardiovascular disease. The company offers CVProfilor DO-2020, which provides a patient's arterial elasticity indices used in the assessment for underlying vascular disease; CVProfilor MD-3000 that offers a sensitive and specific guide to the presence of blood vessel disease; and HD/PulseWave CR-2000 research cardiovascular profiling system, which provides researchers and scientists with a non-invasive means to assess arterial elasticity in support of human research in various areas. Its products collect 30 seconds of blood pressure waveform data, perform an analysis of the digitized blood pressure waveforms, and generate a CVProfile report that contains information on blood pressure, heart rate, pulse pressure, body surface area, body mass index, and C1-large and C2-small artery elasticity indices. The company sells its products to primary care physicians, cardiologists, health care professionals, trained medical personnel, research investigators at academic medical research centers, government institutes, cardiovascular specialists, and pharmaceutical firms. It markets its products through a representative organization in the United States. Hypertension Diagnostics, Inc. was founded in 1988 and is based in Richmond Hill, Canada.

About Microbot Medical

Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.